AstraZeneca plc 20.4% Potential Decrease Indicated by Goldman Sachs

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc using EPIC/TICKER code (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘SELL’ this morning by analysts at Goldman Sachs. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Goldman Sachs have set a target price of 5000 GBX on its stock. This would indicate that the analyst believes there is a downside of -20.4% from today’s opening price of 6283 GBX. Over the last 30 and 90 trading days the company share price has increased 602 points and increased 142 points respectively. The 1 year high for the stock price is 6432.48 GBX while the year low stock price is currently 4746 GBX.

AstraZeneca plc has a 50 day moving average of 5,913.00 GBX and a 200 day moving average of 5,848.42. There are currently 1,267,287,658 shares in issue with the average daily volume traded being 2,316,417. Market capitalisation for LON:AZN is £79,750,412,317 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
    AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

      Search

      Search